Dabigatran and risk of myocardial infarction
- 13 March 2012
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 9 (5) , 260-262
- https://doi.org/10.1038/nrcardio.2012.34
Abstract
Dabigatran has been associated with an increase in acute coronary events when compared with warfarin in several randomized trials, and now in a meta-analysis by Uchino and Hernandez. We critically review the evidence for this association and consider the implications for patient care.Keywords
This publication has 9 references indexed in Scilit:
- Dabigatran Association With Higher Risk of Acute Coronary EventsArchives of internal medicine (1960), 2012
- Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) TrialCirculation, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trialEuropean Heart Journal, 2011
- Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and FlutterCanadian Journal of Cardiology, 2011
- Newly Identified Events in the RE-LY TrialNew England Journal of Medicine, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trialThe Lancet, 2003
- Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' dataThe Lancet, 2002